LCD/NCD Portal

NCD40.7

 

OUTPATIENT INTRAVENOUS INSULIN TREATMENT

 

 

Effective Date of this Version

4/5/2010

 

 

Benefit Category

 

• Diagnostic Tests (other).

• Drugs and Biologicals.

• Physicians' Services.

• Note: This may not be an exhaustive list of all applicable Medicare benefit categories for this item or service.

 

 

Item/Service Description

 

A. General

• The term outpatient intravenous (IV) insulin therapy (OIVIT) refers to an outpatient regimen that integrates pulsatile or continuous intravenous infusion of insulin via any means, guided by the results of measurement of:

o Respiratory quotient.

o Urine urea nitrogen (UUN).

o Arterial, venous, or capillary glucose.

o Potassium concentration.

o Performed in scheduled recurring periodic intermittent episodes.

• This regimen is also sometimes termed

o Cellular Activation Therapy (CAT).

o Chronic Intermittent Intravenous Insulin Therapy (CIIT).

o Hepatic Activation Therapy (HAT).

o Intercellular Activation Therapy (iCAT).

o Metabolic Activation Therapy (MAT).

o Pulsatile Intravenous Insulin Treatment (PIVIT).

o Pulse Insulin Therapy (PIT).

o Pulsatile Therapy (PT).

• In OIVIT, insulin is intravenously administered in the outpatient setting for a variety of indications.

o Most commonly, it is delivered in pulses, but it may be delivered as a more conventional drip solution.

o The insulin administration is adjunctive to the patient's routine diabetic management regimen (oral agent or insulin-based) or other disease management regimen, typically performed on an intermittent basis (often weekly), and frequently performed chronically without duration limits.

o Glucose or other carbohydrate is available ad libitum (in accordance with patient desire).

 

 

Indications and Limitations of Coverage

 

Nationally Covered Indications

N/A

 

 

Nationally Non-Covered Indications

 

• Effective for claims with dates of service on and after December 23, 2009, the Centers for Medicare and Medicaid Services (CMS) determines that the evidence is adequate to conclude that OIVIT does not improve health outcomes in Medicare beneficiaries. Therefore, CMS determines that OIVIT is not reasonable and necessary for any indication under section 1862(a)(1)(A) of the Social Security Act. Services comprising an Outpatient Intravenous Insulin Therapy regimen are nationally non-covered under Medicare when furnished pursuant to an OIVIT regimen (see subsection A. above).

 

 

Other

• Individual components of OIVIT may have medical uses in conventional treatment regimens for diabetes and other conditions.

• Coverage for such other uses may be determined by other local or national Medicare determinations, and do not pertain to OIVIT.

• For example, see Pub. 100-03, NCD Manual, Section 40.2, Home Blood Glucose Monitors, Section 40.3, Closed-loop Blood Glucose Control Devices (CBGCD), Section 190.20, Blood Glucose Testing, and Section 280.14, Infusion Pumps, as well as Pub. 100-04, Claims Processing Manual, Chapter 18, Section 90, Diabetics Screening.

• (This NCD last reviewed December 2009.)

 

 

Claims Processing Instructions

 

• TN 1913 (Medicare Claims Processing)

• TN 1923 (Medicare Claims Processing)

• TN 1930 (Medicare Claims Processing)

 

 

Coverage Transmittal Link

 

http://www.cms.gov/transmittals/downloads/R117NCD.pdf

 

 

National Coverage Analyses (NCAs)

 

• This NCD has been or is currently being reviewed under the National Coverage Determination process.

• The following are existing associations with NCAs, from the National Coverage Analyses database.

• Original consideration for Outpatient Intravenous Insulin Treatment (Therapy) (CAG-00410N) opens in new window

 

 

Medicare NCD Link